Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Lucrative Positions in the Advancing Position Market of 2024 - 2Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- 3The most effective method to Connect Successfully with Teachers in a Web based Setting
- 4The Main 15 Applications for Efficiency and Association
- 5Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- The Force of Care: Living with Goal
- King Charles III says he is reducing cancer treatment schedule in 2026
- The Best Competitors of the 21st Hundred years
- 'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- UK forecast to face weaker growth and higher inflation from Iran war
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- What to know about voluntary chocolate recall
- Turning into a Distributed Writer: My Composing Process
